SCHEMBL1387402

SCHEMBL1387402

C=CCOC(=O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.70
ALDH1A1 P00352 5/20 0.70
LMNA P02545 4/20 0.70
HPGD P15428 4/20 0.70
HSD17B10 Q99714 4/20 0.70
CYP1A2 P05177 1/20 0.70
TOP2A P11388 1/20 0.70
CYP2C9 P11712 1/20 0.70
TOP2B Q02880 1/20 0.70
MAPT P10636 1/20 0.54
TP53 P04637 1/20 0.53
CASP3 P42574 1/20 0.53
CASP9 P55211 1/20 0.53
BAX Q07812 1/20 0.53
BRD4 O60885 1/20 0.50
TSHR P16473 1/20 0.50
HTT P42858 1/20 0.50
CYP2J2 P51589 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50
PIK3CD O00329 3/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ciprofloxacin Ethyl Ester SCHEMBL6779201 0.88 KDM4E (0.74) KDM4EALDH1A1LMNAHPGDHSD17B10
SCHEMBL8799291 0.88 KDM4E (0.62) KDM4EALDH1A1LMNAHPGDHSD17B10
SCHEMBL9500971 0.87 KDM4E (0.81) KDM4EALDH1A1LMNAHPGDHSD17B10
SCHEMBL13923333 0.86 KDM4E (0.79) KDM4EALDH1A1LMNAHPGDHSD17B10
SCHEMBL1387453 0.86 KDM4E (0.70) KDM4EALDH1A1LMNAHPGDHSD17B10
SCHEMBL8983611 0.85 KDM4E (0.78) KDM4EALDH1A1LMNAHPGDHSD17B10
SCHEMBL1706011 0.85 KDM4E (0.69) KDM4EALDH1A1LMNAHPGDHSD17B10
SCHEMBL11967716 0.85 KDM4E (0.71) KDM4EALDH1A1LMNAHPGDHSD17B10
SCHEMBL14616028 0.84 KDM4E (0.68) KDM4EALDH1A1LMNAHPGDHSD17B10
SCHEMBL1890532 0.84 KDM4E (0.70) KDM4EALDH1A1LMNAHPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-H10503521-A 1998-03-31 JP claimed
EP-0775145-A1 PROCESS FOR MAKING QUINOLONYL LACTAM ANTIMICROBIALS AND NOVEL INTERMEDIATE COMPOUNDS THE PROCTER & GAMBLE COMPANY (US) 1997-05-28 EP claimed
EP-0606336-B1 PROCESS FOR MAKING ANTIMICROBIAL QUINOLONYL LACTAMS PROCTER & GAMBLE PHARMA (US) 1997-03-19 EP claimed
WO-1996004286-A1 PROCESS FOR MAKING QUINOLONYL LACTAM ANTIMICROBIALS AND NOVEL INTERMEDIATE COMPOUNDS THE PROCTER & GAMBLE COMPANY (US) 1996-02-15 WO claimed
EP-0606336-A1 PROCESS FOR MAKING ANTIMICROBIAL QUINOLONYL LACTAMS. PROCTER & GAMBLE PHARMA (US) 1994-07-20 EP claimed
CN-1075146-A The method for preparing antimicrobial quinolonyl lactams PROCTER & GAMBLE PHARMA (US) 1993-08-11 CN claimed
WO-1993007154-A1 PROCESS FOR MAKING ANTIMICROBIAL QUINOLONYL LACTAMS PROCTER & GAMBLE PHARMACEUTICALS, INC. (US) 1993-04-15 WO claimed
US-11014891-B2 Reduction-triggered antibacterial sideromycins UNIVERSITY OF NOTRE DAME DU LAC (US) 2021-05-25 US disclosed
US-20160368878-A1 REDUCTION-TRIGGERED ANTIBACTERIAL SIDEROMYCINS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2016-12-22 US disclosed
WO-2015061630-A2 REDUCTION-TRIGGERED ANTIBACTERIAL SIDEROMYCINS MILLER MARVIN J (US) 2015-04-30 WO disclosed
EP-0997466-A1 Novel antimicrobial lactam-quinolones PROCTER & GAMBLE PHARMACEUTICALS, INC. (US) 2000-05-03 EP disclosed
US-5656623-A BACTERICIDES; ANTIBIOTICS THE PROCTER & GAMBLE COMPANY (US) 1997-08-12 US disclosed
US-5648346-A Antimicrobial carbacephem-quinolones THE PROCTER & GAMBLE COMPANY (US) 1997-07-15 US disclosed
US-5646139-A TREATING AND PREVENTING INFECTION THE PROCTER & GAMBLE COMPANY (US) 1997-07-08 US disclosed
US-5637580-A ANTIBIOTICS THE PROCTER & GAMBLE COMPANY (US) 1997-06-10 US disclosed
EP-0606336-B1 PROCESS FOR MAKING ANTIMICROBIAL QUINOLONYL LACTAMS PROCTER & GAMBLE PHARMA (US) 1997-03-19 EP disclosed
EP-0366189-A2 Novel antimicrobial lactam-quinolones Norwich Eaton Pharmaceuticals, Inc. (US) 1990-05-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11014891-B2 Reduction-triggered antibacterial sideromycins HAMP, SLC40A1, FTH1 KDM4E 2741/4885ALDH1A1 4009/4885LMNA 3345/4885
US-20160368878-A1 REDUCTION-TRIGGERED ANTIBACTERIAL SIDEROMYCINS HAMP, SLC40A1, FTH1 KDM4E 2741/4885ALDH1A1 4009/4885LMNA 3345/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.